MedPath
HSA Approval

ARCALION TABLET 200 MG

SIN06159P

ARCALION TABLET 200 MG

ARCALION TABLET 200 MG

May 3, 1991

SERVIER (S) PTE LTD

SERVIER (S) PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantSERVIER (S) PTE LTD
Licence HolderSERVIER (S) PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
General Sale List
HSA Singapore Classification

Formulation Information

TABLET, SUGAR COATED

**DOSAGE** _For adult use only_ – Oral route. 2 to 3 tablets a day. Tablets should be swallowed whole with a large glass of water, dividing the doses between the morning and midday meals. Duration of treatment is limited to 4 weeks. _This drug has been dispensed to you personally in a specific situation:_ - _It cannot be adapted to another case,_ - _Do not recommend it to another person_

ORAL

Medical Information

**THERAPEUTIC INDICATION** Certain states of transient fatigue in adults (over 15 years old).

**CONTRAINDICATIONS** Hypersensitivity to the active substance or to any of the excipients. _If in doubt, you must ask your physician or your pharmacist for advice._

A11DA02

sulbutiamine

Manufacturer Information

SERVIER (S) PTE LTD

LES LABORATOIRES SERVIER INDUSTRIE

Active Ingredients

SULBUTIAMINE

200 mg

Sulbutiamine

Documents

Patient Information Leaflets

Arcalion PIL.pdf

Approved: April 3, 2018

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

ARCALION TABLET 200 MG - HSA Approval | MedPath